指南与共识前列腺癌

EAU-EANM-ESTRO-ESUR-ISUP-SIOG前列腺癌指南第二部分-2024更新:复发性和转移性前列腺癌的治疗

EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer.
指南 / 共识 · Eur Urol · 2024-04-29

欧洲泌尿外科学会等多学科联合更新2024版复发、转移及去势抵抗性前列腺癌治疗指南,基于2020至2023年文献综述,并为每条推荐新增证据强度评级,强调风险分层可指导挽救治疗决策,新型治疗选择已可用于转移性前列腺癌患者。

要点

  • 原发治疗后复发前列腺癌的风险分层可能指导挽救治疗决策。
  • 转移性前列腺癌可选雄激素受体靶向药物、PARP抑制剂及前列腺特异性膜抗原靶向治疗等。
  • 指南反映前列腺癌管理的多学科性质,每年更新。

核心结论

  • 复发、转移及去势抵抗性前列腺癌的证据正在快速演变,本指南反映了前列腺癌管理的多学科性质。

研究设计与样本

  • 由欧洲泌尿外科学会、欧洲核医学协会、欧洲放射肿瘤学会、欧洲泌尿生殖放射学会、国际泌尿病理学会和国际老年肿瘤学会联合制定,基于2020至2023年文献综述更新,并对每条推荐新增基于系统证据评价的强度评级。

主要发现

  • 原发治疗后复发前列腺癌的风险分层可能指导挽救治疗决策。
  • 雄激素受体靶向药物、雄激素受体靶向药物联合化疗、PARP抑制剂及其联合方案、以及基于前列腺特异性膜抗原的治疗等新选择已可用于转移性前列腺癌男性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: The European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Urological Pathology (ISUP)-International Society of Geriatric Oncology (SIOG) guidelines on the treatment of relapsing, metastatic, and castration-resistant prostate cancer (PCa) have been updated. Here we provide a summary of the 2024 guidelines. METHODS: The panel performed a literature review of new data, covering the time frame between 2020 and 2023. The guidelines were updated and a strength rating for each recommendation was added on the basis of a systematic review of the evidence. KEY FINDINGS AND LIMITATIONS: Risk stratification for relapsing PCa after primary therapy may guide salvage therapy decisions. New treatment options, such as androgen receptor-targeted agents (ARTAs), ARTA + chemotherapy combinations, PARP inhibitors and their combinations, and prostate-specific membrane antigen-based therapy have become available for men with metastatic PCa. CONCLUSIONS AND CLINICAL IMPLICATIONS: Evidence for relapsing, metastatic, and castration-resistant PCa is evolving rapidly. These guidelines reflect the multidisciplinary nature of PCa management. The full version is available online (http://uroweb.org/guideline/ prostate-cancer/). PATIENT SUMMARY: This article summarises the 2024 guidelines for the treatment of relapsing, metastatic, and castration-resistant prostate cancer. These guidelines are based on evidence and guide doctors in discussing treatment decisions with their patients. The guidelines are updated every year.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Tilki D, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2024. PMID: 38688773. doi:10.1016/j.eururo.2024.04.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。